Biologic Therapies for Giant Cell Arteritis

Robert Harrington,* Shamma Ahmad Al Nokhatha,* Richard Conway Department of Rheumatology, St. James’s Hospital, Dublin, Ireland*These authors contributed equally to this workCorrespondence: Richard ConwayDepartment of Rheumatology, St. James’s Hospital, James Street, Dublin 8, Ir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Harrington R, Al Nokhatha SA, Conway R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	giant cell arteritis biologics glucocorticoids Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/22c6799b78d44b8195de3ff95920067f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22c6799b78d44b8195de3ff95920067f
record_format	dspace
spelling	oai:doaj.org-article:22c6799b78d44b8195de3ff95920067f2021-12-02T15:07:16ZBiologic Therapies for Giant Cell Arteritis1177-5491https://doaj.org/article/22c6799b78d44b8195de3ff95920067f2021-01-01T00:00:00Zhttps://www.dovepress.com/biologic-therapies-for-giant-cell-arteritis-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Robert Harrington,* Shamma Ahmad Al Nokhatha,* Richard Conway Department of Rheumatology, St. James’s Hospital, Dublin, Ireland*These authors contributed equally to this workCorrespondence: Richard ConwayDepartment of Rheumatology, St. James’s Hospital, James Street, Dublin 8, IrelandTel +353-14103721Fax +353-12836099Email drrichardconway@gmail.comAbstract: Glucocorticoids have been the mainstay of treatment in giant cell arteritis (GCA) for the past 70 years. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) have largely failed to show significant clinical efficacy or reduction of the glucocorticoid burden in GCA. Tocilizumab is the first biologic to make a substantial impact in GCA treatment. With the current understanding of GCA pathogenesis implicating multiple cytokines, notably interleukin (IL) 6, IL-12, IL-23, IL-1β, and the role of janus kinases (JAKs) and the signal transducer and activator of transcription (STAT) pathway in these cytokines, many biologics are currently being investigated in GCA. This review article looks at the existing evidence for biologic agents in GCA. In addition to tocilizumab, the potential role of ustekinumab, abatacept, JAK inhibitors and other promising biologics in GCA are discussed in detail. A treatment algorithm based on the best evidence to date is also presented.Keywords: giant cell arteritis, biologics, glucocorticoidsHarrington RAl Nokhatha SAConway RDove Medical Pressarticlegiant cell arteritisbiologicsglucocorticoidsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 17-29 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	giant cell arteritis biologics glucocorticoids Medicine (General) R5-920
spellingShingle	giant cell arteritis biologics glucocorticoids Medicine (General) R5-920 Harrington R Al Nokhatha SA Conway R Biologic Therapies for Giant Cell Arteritis
description	Robert Harrington,* Shamma Ahmad Al Nokhatha,* Richard Conway Department of Rheumatology, St. James’s Hospital, Dublin, Ireland*These authors contributed equally to this workCorrespondence: Richard ConwayDepartment of Rheumatology, St. James’s Hospital, James Street, Dublin 8, IrelandTel +353-14103721Fax +353-12836099Email drrichardconway@gmail.comAbstract: Glucocorticoids have been the mainstay of treatment in giant cell arteritis (GCA) for the past 70 years. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) have largely failed to show significant clinical efficacy or reduction of the glucocorticoid burden in GCA. Tocilizumab is the first biologic to make a substantial impact in GCA treatment. With the current understanding of GCA pathogenesis implicating multiple cytokines, notably interleukin (IL) 6, IL-12, IL-23, IL-1β, and the role of janus kinases (JAKs) and the signal transducer and activator of transcription (STAT) pathway in these cytokines, many biologics are currently being investigated in GCA. This review article looks at the existing evidence for biologic agents in GCA. In addition to tocilizumab, the potential role of ustekinumab, abatacept, JAK inhibitors and other promising biologics in GCA are discussed in detail. A treatment algorithm based on the best evidence to date is also presented.Keywords: giant cell arteritis, biologics, glucocorticoids
format	article
author	Harrington R Al Nokhatha SA Conway R
author_facet	Harrington R Al Nokhatha SA Conway R
author_sort	Harrington R
title	Biologic Therapies for Giant Cell Arteritis
title_short	Biologic Therapies for Giant Cell Arteritis
title_full	Biologic Therapies for Giant Cell Arteritis
title_fullStr	Biologic Therapies for Giant Cell Arteritis
title_full_unstemmed	Biologic Therapies for Giant Cell Arteritis
title_sort	biologic therapies for giant cell arteritis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/22c6799b78d44b8195de3ff95920067f
work_keys_str_mv	AT harringtonr biologictherapiesforgiantcellarteritis AT alnokhathasa biologictherapiesforgiantcellarteritis AT conwayr biologictherapiesforgiantcellarteritis
_version_	1718388437082439680

Biologic Therapies for Giant Cell Arteritis

Ejemplares similares